Anthem Biosciences Limited has informed the Exchange regarding Allotment of 14,81,250 equity shares pursuant to the exercise of stock options under Anthem Employee Stock Option Plan 2024
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences reported strong FY2026 results with standalone revenue of ₹20,893 million (up 13.5%) and profit before tax of ₹9,031 million (up 27%). The Board approved allotment of 14,81,250 equity shares (1.48 million shares) to employees exercising options under the ESOP 2024 scheme, increasing paid-up capital from ₹1,123.43 million to ₹1,126.39 million. A final dividend of ₹2 per share (100% payout) was recommended for FY2026, with record date June 26, 2026. The 20th AGM is scheduled for July 22, 2026. The company listed on NSE/BSE in July 2025 at ₹570 per share. Auditors gave an unmodified opinion on the financials.
The ESOP allotment is dilutive to existing shareholders by ~2.6% but aligns employee interests with performance. The 27% growth in pre-tax profit and doubled annualised EPS signal strong operational performance. The 100% dividend payout demonstrates confidence in cash generation.